【摘要】 目的 探讨替吉奥胶囊联合奥沙利铂治疗晚期胃癌的近期疗效和毒性反应。 方法 2010年1-7月，16例晚期胃癌患者根据体表面积来确定初始剂量，体表面积lt;1.25 m2，替吉奥胶囊40 mg/次，2次/d；体表面积1.25~1.5 m2，替吉奥胶囊50 mg/次，2次/d；体表面积gt;1.5 m2，替吉奥胶囊60 mg/次，2次/d，早、晚饭后分别口服1次，连续服用28 d，停药14 d。奥沙利铂注射液130 mg/m2加入5%葡萄糖注射液500 mL避光缓慢静gt;2 h，第1、21天重复，连用2周期。按RECIST 1.1标准评价客观疗效和不良反应。 结果 16例患者中PR 9例（56.3%），SD3例（18.8%），PD 4例（25%），总有效率为69.0%。不良反应主要是血液学毒性、胃肠道反应及外周神经毒性，且均在Ⅰ~Ⅱ。 结论 替吉奥胶囊联合奥沙利铂方案治疗晚期胃癌的近期疗效较好，不良反应可以耐受，值得进一步研究应用。【Abstract】 Objective To explore the early efficacy of Oxaliplatin combined with S1 capsule on advanced gastric cancer and observe the toxicity. Methods A total of 16 patients with advanced gastric cancer from January to July 2010 were treated with chemotherapy: oxaliplatin 130 mg/m2 mixed with 5% glucose injection 500 mL in the first day and repeated in the 21st day; Po after breakfast and dinner: S1 capsule with an initial dose according to the body surface area. Body surface lt;1.25 m2, 40 mg once, twice per day; body surface:1.25-1.5 m2,50 mg once, twice per day; body surface gt;1.5 m2, 60 mg once, twice per day. The medication lasted for 28 days, withdrew for 14 days. All of the patients underwent the treatment for two cycles. Efficacy and toxicities were evaluated according to the RECIST 1.1 standard. Results Of the 16 patients, partial remission (PR) was in nine (56.3%), stable disease was in three (18.8%) (SD), and progression disease was in four (PD). The total response rate was 69.0%. The major toxicities included leucopenia, nausea, vomiting and neurosensory abnormity. Conclusion Oxaliplatin combined with S1 capsule is effective on advanced gastric cancer, and the adverse effects are tolerable.
ObjectiveTo observe the anticancer efficacy of ginsenoside Rg3 on colorectal cancer in vitro and in vivo. MethodsMice colorectal cell line (CT26) was incubated in 96-well plates (3×103-4×103 per well) with various concentrations of ginsenoside Rg3 (0, 5, 10, 15, 20 μg/mL) for 24 hours and 48 hours. 3-(4, 5-dimethyl-2-thiazolyl)-2, 5-dipheny 1-2-H-tetrazolium bromide assay was used to detect the inhibitory rate of cells. Xenograft models were established by subcutaneous implantation of CT26 cells into BABL/c mice. Each mouse was injected with 1×107 cells suspended in serum-free medium. Xenograft mice were randomized into four groups: physiological saline group, ginsenoside Rg3 5 mg/kg group, ginsenoside Rg3 10 mg/kg group, and ginsenoside Rg3 20 mg/kg group. Ginsenoside Rg3 was administrated to mice by intragastric gavage. All animals were observed for activity, body weight, tumor size, survival time, mental state and adverse effect of ginsenoside Rg3. Hematoxylin-eosin stain was used for comparing necrosis rate among groups. ResultsThe inhibitory rates of cells were increasing following the elevating concentrations of ginsenoside Rg3. The anti-proliferation effect of ginsenoside Rg3 for 48 hours was weaker than the anti-proliferation effect for 24 hours. The decrease of mice body weight was slower than physiological saline group after administration of ginsenoside Rg3, and the number of mice with worse physiological state, lack of activity and loss of appetite in physiological saline group were more than that in ginsenoside Rg3 groups. However, these results among four groups were not significantly different (P>0.05). There were no obvious adverse effects of ginsenoside Rg3 found during the whole study. The necrosis rate of physiological saline group, Rg3 10 mg/kg group and Rg3 20 mg/kg group was 20%, 60% and 80% respectively. ConclusionGinsenoside Rg3, as a single agent, still has anticancer activity. The anticancer efficacy is increasing following the elevating concentrations of ginsenoside Rg3. Ginsenoside Rg3 is a dose dependent agent.